NOW FDA APPROVED FOR COLORECTAL CANCER (CRC) SCREENING

Press and publications

Back to Resources
card-image
Guardant Health’s Shield™ Blood Test Named to TIME’s List of the Best Inventions of 2024

TIME’s annual list of the Best Inventions features 200 extraordinary innovations changing lives.

Read more
card-image
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening

Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates

Read
card-image
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening Published in The New England Journal of Medicine

ECLIPSE validates Shield as an accurate screening method for CRC

Read
card-image
Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer

Study demonstrates 83% sensitivity for detection of colorectal cancer with specificity of 90%

Read
card-image
Validation of a multimodal blood-based test for the detection of colorectal cancer with sub single molecule sensitivity

Blood-based colorectal cancer (CRC) screening tests can improve adherence to screening guidelines

Read
card-image
A New Simpler Blood Test To Screen For Colorectal Cancer May Help Save More Lives

Colorectal cancer (CRC) remains one of the most common and deadly forms of cancer in the United States

Read
card-image
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults

Highly sensitive Shield test offers convenient screening method that can be completed with simple blood draw

Read
card-image
Development of a Highly-Sensitive Targeted Cell-Free DNA Epigenomic Assay for Early-Stage Multi-Cancer Screening

A blood-based cancer screening test should exhibit performance metrics optimized for the cancer of interest

Read
card-image
Close the Gap: Disparities in Cancer Screening Threaten Lives

February marks National Cancer Prevention Month, an initiative to bring awareness to ways Americans can reduce their risk for cancer

Read

Important Product Information

Intended Use

The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit.
Shield is indicated for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. This test is performed at Guardant Health, Inc.

Precaution: Based on data from clinical studies, Shield has limited detection (55%-65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy. Shield demonstrated high detection of Stage II, III, and IV colorectal cancer.

Limitations and Other Important Information: The Shield test is not indicated for patients that have personal history of colorectal cancer, adenomas, or other related cancers; or those who had a positive result on another colorectal cancer screening method within the last six months, have been diagnosed with a condition associated with high risk for colorectal cancer such as Inflammatory Bowel Disease (IBD), chronic ulcerative colitis (CUC), Crohn’s disease; or who have a family history of colorectal cancer, or certain hereditary syndromes. Providers should discuss the most appropriate screening test to use with patients depending on their medical history and individual circumstances. Shield may produce a false negative or false positive result. A false negative result may occur when the Shield test does not detect a colorectal tumor signal while a colonoscopy identifies a colorectal cancer. A negative result does not guarantee the absence of colorectal cancer or advanced adenoma, and patients should continue participating in colorectal cancer screening programs at the appropriate guideline-recommended intervals. A false positive result may occur when the Shield test generates a positive result while a colonoscopy will not find colorectal cancer or advanced adenoma.

Please read our Provider Brochure for complete product information about the Shield test including full safety information.